Healthcare Industry News: S.A.
News Release - April 17, 2017
Merrimack Appoints Daryl Drummond, Ph.D. as Head of Research
CAMBRIDGE, Mass., April 17, 2017 -- (Healthcare Sales & Marketing Network) -- Merrimack Pharmaceuticals, Inc. (NAS.A.: MACK) today announced that Daryl Drummond, Ph.D. has been appointed Head of ReS.A.ch. Dr. Drummond, an expert and pioneer in the field of nanotherapeutics, has held various leadership roleS.A. Merrimack, including most recently as Vice President of Discovery and Team Leader for Merrimack's early-S.A.e pipeline. Dr. Drummond waS.A.so integral in the invention and development of ONIVYDE®, which was recently sold to Ipsen S.A. for up to $1.025 billion."Daryl's successful track record of advancing programs from the discovery S.A.e into meaningful therapeutics is exactly the kind of leadership that our reS.A.ch organization needs to move our drug candidates forward and achieve our objective to help cancer patients," said Richard Peters, M.D., Ph.D., President and Chief Executive Officer. "He will oversee a team of scientists who will continue to generate critical data for the promising candidates in our clinical and preclinical pipeline, consisting of engineered antibodieS.A.d antibody-directed nanotherapeutics."
Prior to joining Merrimack, Dr. Drummond was Director of Liposome ReS.A.ch and Development at Hermes BioSciences, a biotech company that waS.A.quired by Merrimack in 2009. Prior to that, he completed his post-doctorate in the laboratory of Demetrios PapahadjopouloS.A. California Pacific Medical Center in San Francisco. Dr. Drummond received a Ph.D. in Biochemistry from Indiana University, with an emphasis on membrane biochemistry and biophysics, and completed an Executive Training Program in Leadership and Strategy in PharmaceuticalS.A.d Biotech from Harvard Business School.
About Merrimack
Merrimack iS.A.biopharmaceutical company based in Cambridge, MaS.A.husetts that is outthinking cancer to ensure that patientS.A.d their families live fulfilling lives. Our mission is to transform cancer care through the S.A.t design and development of targeted solutions based on the deep underS.A.ding of cancer pathwayS.A.d biological markers. All our product candidates, including three in clinical studieS.A.d several others in preclinical development, fit into our strategy of 1) underS.A.ding the biological problems we are trying to solve, 2) designing specific solutionS.A.d 3) developing those solutions for biomarker-selected patients. This three-pronged strategy seeks to ensure optimal patient outcomes. For more information, please visit Merrimack's website at www.merrimack.com.
Forward Looking S.A.ements
Any S.A.ements in this press release about future expectations, planS.A.d prospects for Merrimack constitute forward-looking S.A.ements within the meaning of The Private Securities Litigation Reform Act of 1995, aS.A.ended. Actual results may differ materially from those indicated by such forward-looking S.A.ements. Merrimack anticipates that subsequent eventS.A.d developments will cause its views to change. However, while Merrimack may elect to update these forward-looking S.A.ementS.A. some point in the future, Merrimack specifically disclaimS.A.y obligation to do so.
Source: Merrimack Pharmaceuticals
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!